New Therapeutic Advances: Skin Cancer and Actinic Keratoses

A supplement to Skin & Allergy News supported by an unrestricted educational grant from ICN Pharmaceuticals, Inc.
Highlights of presentations made at a regional continuing medical education meeting held November 9, 2002, in Newport Beach, Calif.

•Contents
•Target Audience
•Educational Needs
•Learning Objectives
•Accreditation

To view the supplement, click the image above. To take the CME test, download and print out the PDF file, and follow the test instructions on page 15.

Contents

Update on Melanoma
Nancy J. Anderson, MD
Professor, Division of Dermatology
Director, Dermatology Residence Program
Loma Linda University
Chief, Division of Dermatology
Veterans Administration Medical Center
Loma Linda, Calif.
Speaker's Bureau: ICN Pharmaceuticals, Inc. Discusses unlabeled or investigational uses of imiquimod and 5-fluorouracil.

Common Nonmelanoma Skin Cancers: Basal Cell Carcinoma and Squamous Cell Carcinoma
Nancy J. Anderson, MD
Edward W. Jeffes III, MD, PhD

Actinic Keratosis: Current Approaches to Management
Nancy J. Anderson, MD
Edward W. Jeffes III, MD, PhD

5-Fluorouracil Therapy: Clinical Tips and Issues
Edward W. Jeffes III, MD, PhD
Associate Professor, Department of Dermatology
University of California-Irvine
Associate Chief of Dermatology Service
Veterans Administration Medical Center
Long Beach, Calif.
Speaker's Bureau: ICN Pharmaceuticals, Inc. Grant Support and Consultant: ICN and DUSA Pharmaceuticals. Discusses the unlabeled or investigational use of 5-fluorouracil for treating actinic cheilitis as well as photodamaged skin.
Target Audience

This activity has been developed for dermatologists and other health care professionals involved in the treatment of patients at risk for melanoma, nonmelanoma skin cancers, and actinic keratosis.

Educational Needs

The incidence of melanoma, nonmelanoma skin cancers, and the squamous cell carcinoma precursor, actinic keratosis, is high and has been increasing steadily. Dermatologists must remain abreast of the current recommendations for the diagnosis and treatment of these lesions.

Learning Objectives

By reading and studying this supplement, participants should be able to:

• Discuss the incidence and risk factors associated with melanoma and nonmelanoma skin cancers as well as the treatment modalities currently available.

• Identify treatment options for various subgroups of patients within the above categories (for example, those who are receiving immunosuppressant therapy after solid organ transplantation).

• Describe the relationship between actinic keratosis and squamous cell carcinoma.

• Explain the role of 5-flourouracil therapy and the dosing options available to reduce the side effects associated with such treatment.

Accreditation

This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of the University of Kentucky College of Medicine and Skin & Allergy News. The University of Kentucky College of Medicine is accredited by the ACCME to provide continuing medical education for physicians.

The University of Kentucky College of Medicine designated this educational activity for a maximum of 1 hour in Category 1 credit toward the AMA Physician's Recognition Award. Each physician should claim only those hours of credit actually spent in the educational activity.

The University of Kentucky College of Medicine presents this activity for educational purposes only. Participants are expected to utilize their own expertise and judgment while engaged in the practice of medicine. The content of the presentations is provided solely by presenters who have been selected for presentations because of recognized expertise in their field.

Copyright © 2003 by International Medical News Group

---